Addex and Merck & Co., Inc. Collaborate to Develop Drugs for Parkinson's Disease
Collaboration Targets a Non-Dopaminergic Approach to Treating Parkinson's Disease
04-Dec-2007 -
Addex Pharmaceuticals announced that it has entered an exclusive collaboration and license agreement with Merck & Co., Inc. (through its affiliate Merck Sharp & Dohme Research Ltd) with the goal of developing a new class of orally available drugs, initially as candidates for the treatment of ...
license agreements
Merck
Parkinson's disease